SGLT2 Inhibitors Can Reduce Tumor Growth
Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.
One reason for the unsustainable growth of tumors is their independence from regulatory pathways that ensure normalcy of cellular metabolism. However, activation of oncogenes and loss of tumor suppressors in cancer promote metabolic reprogramming, resulting in enhanced nutrient uptake and cancer progression. Intervention with these metabolic pathways could potentially provide a therapeutic advantage to prevent resistance to chemotherapy or radiotherapy.
Now, researchers at the University of California in Los Angeles have discovered that pancreatic and prostate adenocarcinomas express the glucose transporter SGLT2 (sodium-dependent glucose transporter), which actively imports glucose into cancer cells. Inhibiting SGLT2, the authors claim in their paper published in the
“This is exciting because it provides strong evidence that SGLT2 inhibitors, such as those currently approved by the FDA to treat diseases like diabetes, could potentially block glucose uptake and reduce tumor growth and survival in pancreatic and prostate cancers,” said Dr Ernest Wright, professor of physiology and lead author of the study, in an
The researchers first used surgical tumor specimens to conduct transporter assays—this confirmed the expression of SGLT2 in human pancreatic and prostate cancers. Then, using a mouse xenograft model of pancreatic cancer, the authors examined tumor growth and survival in the presence and absence of SGLT2 inhibitors (
The authors plan to follow-up their study with a clinical trial to test SGLT2 inhibitors in pancreatic and prostate cancer patients.
Pancreatic cancer is the fourth-leading cause of cancer-related death in the United States, with a mortality that nearly matches disease incidence and a dismal 5-year survival rate of 7%. Prostate cancer follows lung cancer as the second leading cause of cancer-related death among men in the United States.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025